挪威猝倒性睡眠发作的患病率。
Prevalence of narcolepsy with cataplexy in Norway.
机构信息
Norwegian Resource Center for AD/HD, Tourettes Syndrome and Narcolepsy, Ullevål University Hospital, Oslo, Norway.
出版信息
Acta Neurol Scand. 2009 Oct;120(4):276-80. doi: 10.1111/j.1600-0404.2009.01166.x. Epub 2009 May 15.
OBJECTIVES
Narcolepsy is a lifelong disabling disorder that may be alleviated by relevant treatment. Patients frequently report 10-15 years from the first symptoms to the time they get the diagnosis and treatment can be started. In order to offer a sufficient diagnostic and therapeutic service to this patient group, a reliable estimation of the prevalence of the disorder is important. A study of the prevalence of narcolepsy with cataplexy in Norway was therefore undertaken.
MATERIALS AND METHODS
The Ullanlinna Narcolepsy scale (UNS) was sent to 14548 randomly selected Norwegians between 20 and 60 years. Additionally, the study included telephone interviews and clinical evaluation of responders with >or=14 points on the UNS, and in those with suspected narcolepsy, polygraphic sleep recordings and human leucocyte antigen (HLA)-typing.
RESULTS
A total of 8992 responders answered the questionnaire (response rate 61.8%), 267 had >or=14 points on the UNS, 156 were interviewed and 15 had sleep recordings. In two HLADQB1*0602-positive patients sleep recordings were compatible with narcolepsy.
CONCLUSIONS
The results indicate a prevalence of 0.022% and approximately 1000 patients with narcolepsy with cataplexy in Norway.
目的
发作性睡病是一种终身致残的疾病，可通过相关治疗缓解。患者通常在出现症状后 10-15 年才得到诊断和治疗。为了向这群患者提供充分的诊断和治疗服务，对该疾病的流行程度进行可靠的评估很重要。因此，在挪威开展了一项伴猝倒发作的发作性睡病流行情况研究。
材料和方法
向 14548 名年龄在 20 至 60 岁之间的挪威人随机寄出了 Ullanlinna 发作性睡病量表（UNS）。此外，对于 UNS 得分＞14 分的应答者，本研究还包括电话访谈和临床评估，对于疑似发作性睡病者，进行多导睡眠图记录和人类白细胞抗原（HLA）分型。
结果
共有 8992 名应答者回答了问卷（应答率 61.8%），其中 267 名 UNS 得分＞14 分，156 名应答者接受了访谈，15 名应答者进行了睡眠记录。在两名 HLA-DQB1*0602 阳性患者中，睡眠记录符合发作性睡病。
结论
结果表明，挪威发作性睡病伴猝倒的患病率为 0.022%，约有 1000 名患者。
Zotero 插件